The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis

Yonsei Medical Journal

Volumn 45, Issue 2, 2004, Pages 199-206

  Goo, Young Suck ^a   Park, Hyeong Cheon ^a   Choi, Hoon Young ^a   Kim, Beom Seok ^a   Park, Yong Beom ^a   Lee, Soo Kon ^a   Kang, Shin Wook ^a   Kim, Soon Il ^a   Kim, Yu Seun ^a   Park, Ki Il ^a   Lee, Ho Yung ^a   Han, Dae Suk ^a   Choi, Kyu Hun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

End stage renal disease; Lupus disease activity; Systemic lupus erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PERITONEAL DIALYSIS; PROGNOSIS; REVIEW; SCORING SYSTEM; SEROLOGY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 2442662695     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.2.199     Document Type: Review

References (24)

1. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000;160:3136-40.
2. Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993; 21:2-8.
3. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
4. Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, et al. A multicenter study of outcome in systemic lupus erythematosus: I. Entry variables as predictors of prognosis. Arthritis Rheum 1982;25:601-11.
5. Fries JF, Powers R, Kempson RL. Late-stage lupus nephropathy. J Rheumatol 1974;1:166-75.
6. Jarrett MP, Santhanam S, Del GF. The clinical course of end-stage renal disease in systemic lupus erythematosus. Arch Intern Med 1983;143:1353-6.
7. Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic lupus erythematousus in patients with end-stage renal disease: A long-term follow up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990;16:189-95.
8. Copolon NS, Dishin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematous in end-stage renal disease. N Engl J Med 1983; 308:186-90.
9. Correia P, Cameron JS, Ogg CS, Williams DG, Bewick M, Micks JA. End-stage renal failure in systemic lupus erythematousus with nephritis. Clin Nephrol 1984;22: 293-302.
10. Rodby RA, Karbet SM, Lewis EJ. Persistence of clinical and serological activity in patients with systemic lupus erythematous undergoing peritoneal dialysis. Am J Med 1987;83:613-8.
11. Cantaluppi A. CAPD and systemic disease. Clin Nephrol 1998;309 Suppl 1:S8-12.
12. Wu GG, Gelbart DR, Husbargen AJ, Imman R, Mcname P, Oreopoulous DG. Reactivation of systemic lupus erythematosus in three patients undergoing CAPD. Peritoneal Dial Bull 1986;6:6-9.
13. Krane NK, Burjak K, Archie M, Donovan RO. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis 1999;33:872-9.
14. Szeto C, Li PK, Wong TY, Leung C, Lui SF. Factors associated with active systemic lupus erythematosus after endstage renal disease. J Rheum 1998;25:1520-5.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Deviation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
16. Goldblum SE, Reed WP. Host defences and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 1980;93:597-613.
17. Raska K Jr, Raskova J, Shea SM, Frankel RM, Wood RH, Litter J. T cell subsets and cellular immunity in end stage renal disease. Am J Med 1983;75:734-40.
18. Lonnemann G, Haubitz M, Schindler R. Hemodialysis associated induction of cytokines. Blood Purif 1990;8: 214-22.
19. Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993;2: 883-91.
20. Hiatt MP, Pyle WK, Moncrief JW, Popovich RP. A comparison of the relative efficacy of CAPD and hemodialysis in the control of solute concentration. Artif Organs 1980;4:37-43.
21. Grzegorzewska AE, Leander M. Lymphocyte subsets in the course of continuous ambulatory peritoneal dialysis. Adv Perit Dial 2001;17:10-4.
22. Rapoport J, Hausmann MJ, Chaimovitz C. The peritoneal immune system and continuous ambulatory peritoneal dialysis. Nephron 1999;81:375-80.
23. Pollack CA, Ibels LS. Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. Aust NZ J Med 1987;17:321-5.
24. Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis 2000;35:611-6.